TipHub

1,575

+44.24 +2.89%

As of 27 Jul 2026 · delayed

NSE Listed

LT-ASM · ASM 4
What does LT-ASM · ASM 4 mean?
BSE · Long Term Additional Surveillance Measure (ASM 4)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-06-11
NSE · Long Term Additional Surveillance Measure (ASM 4)LT-ASM is the joint SEBI/exchange framework for SUSTAINED abnormal price moves (contrast ST-ASM's 5–15-day spikes). Entry is beta-adjusted price variation versus the Nifty (e.g. 3-month high-low above 150% plus the stock's β × index move) along with client-concentration checks. Stages I–IV escalate from a 5% price band through 100% margin to Trade-for-Trade with an additional surveillance deposit. Practical meaning: the exchange still considers the price action abnormal — tighter bands and elevated margins continue even if another measure (like ESM) has lifted. A stock can sit under LT-ASM on both exchanges via either exchange's shortlisting; it is a preventive cost-of-speculation measure, not an adverse finding against the company.Criteria: High 3-month / 12-month high-low price variation, close-to-close price variation, client concentration, number of price-band hits, market-wide position limit and P/E — applied in graded Stages I–IV with escalating margin and price-band curbs.Exchange notice · 2026-07-14

Venus Remedies Limited (VENUSREM)

Volume: 70,003Avg Vol 1W: 61,150.4Avg Vol 1M: 55,089.352W Range:4242,044.3
Key Ratios
Checked 1d ago
Market Cap₹2,204 Cr
Current Price₹1,575
Previous Close₹1,530.76
High / Low (52w)₹2,044.3 / ₹424
Volume70,003
Avg Vol (1W)61,150.4
Avg Vol (1M)55,089.3
Stock P/E7.62
Book Value₹441.01
Dividend Yield
ROE8.1%
ROA
Revenue (TTM)₹669 Cr
Revenue Growth
Profit Margin
Total Debt₹0 Cr
Shares Outstanding
Face Value₹10
EPS (TTM)₹39.32
P/B0.68
Debt / Equity0.04
50 DMA₹1,691.78
200 DMA₹997.26
Day change+2.89%
SurveillanceLT-ASM · ASM 4
Price Chart
1,575 205.83% · 1Y
19474318.8L
2025-07-29
2026-07-27

20-day avg volume: 55K shares

Pros
  • Company is almost debt-free.
  • Stock trades below its book value.
Cons
  • Revenue fell 39% YoY.
  • Company is loss-making at the latest annual result.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹170 Cr₹177 Cr₹195 Cr₹137 Cr₹193 Cr₹180 Cr₹259 Cr₹179 Cr
EBITDA₹9 Cr₹15 Cr₹31 Cr₹13 Cr₹27 Cr₹33 Cr₹62 Cr₹30 Cr
Net Profit₹4 Cr₹20 Cr₹21 Cr₹10 Cr₹20 Cr₹26 Cr₹48 Cr₹23 Cr
EPS
Profit & Loss (Annual)
MetricDec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹172 Cr₹669 Cr₹197 Cr₹137 Cr₹193 Cr₹180 Cr₹259 Cr₹179 Cr
EBITDA₹19 Cr₹62 Cr₹25 Cr₹15 Cr₹26 Cr₹33 Cr₹58 Cr₹33 Cr
Net Profit₹24 Cr₹45 Cr₹15 Cr₹12 Cr₹19 Cr₹25 Cr₹43 Cr₹26 Cr
EPS33.9
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹751 Cr₹733 Cr₹644 Cr₹556 Cr₹580 Cr₹601 Cr₹627 Cr₹716 Cr
Total Liabilities₹389 Cr₹400 Cr₹320 Cr₹156 Cr₹139 Cr₹141 Cr₹139 Cr₹155 Cr
Equity₹362 Cr₹333 Cr₹323 Cr₹400 Cr₹440 Cr₹460 Cr₹488 Cr₹561 Cr
Total Debt
Cash Flow
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹31 Cr₹45 Cr₹63 Cr₹108 Cr₹41 Cr₹37 Cr₹53 Cr₹101 Cr
Investing₹-11 Cr₹-11 Cr₹-5 Cr₹56 Cr₹-17 Cr₹-51 Cr₹-7 Cr₹-76 Cr
Financing₹-39 Cr₹-35 Cr₹-73 Cr₹-162 Cr₹-9 Cr₹-1 Cr₹-1 Cr₹-1 Cr
Free Cash Flow₹18 Cr₹45 Cr₹63 Cr₹108 Cr₹41 Cr₹37 Cr₹53 Cr₹101 Cr
Shareholding
Promoter 41.76% Institutions 3.81% Public 54.43%
Efficiency & Working Capital
ROCE19.8%
Interest Coverage862.1
Dividend Payout
Debtor Days63 d
Inventory Days57 d
Payable Days52 d
Cash Conversion Cycle68 d
Working Capital Days120 d
Shareholding Details

As of 2026-06-30

Promoter41.8%
FII2.9%
DII0.9%
Institutions3.8%
Public54.4%
Promoter Pledge0%
No. of Shareholders21,905
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%41.8%
FIIs1%1.6%1.5%1.1%1.2%1.1%1.3%2.2%1.9%2.3%2.8%2.9%
DIIs0.1%0.1%0.1%0.1%0.1%0%0%0.1%0.7%1%1.2%0.9%
Public57.1%56.5%56.6%57%56.9%57.1%56.9%55.9%55.6%55%54.2%54.4%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders19,26719,56019,91319,61419,55719,77119,98219,30717,72518,60618,40321,905
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Sunev Pharma Solutions Pvt LtdShareholding of Promoter and Promoter Group17.2%23,00,000
Pawan ChaudharyShareholding of Promoter and Promoter Group12.8%17,13,946
Manu ChaudharyShareholding of Promoter and Promoter Group11.7%15,68,000
Tikri Partners LlpPublic Shareholding2%2,62,700
Rajni Tarun JainPublic Shareholding1.4%1,90,000
Acadian Emerging Markets Micro-cap Equity Master FundPublic Shareholding1.1%1,47,501
Nisarg Ajaykumar VakhariaPublic Shareholding1.1%1,40,000
Spine Software Systems Pvt LtShareholding of Promoter and Promoter Group0%0
Tark Ai Pvt LtdShareholding of Promoter and Promoter Group0%0
Radha Luxmi InvestmentsShareholding of Promoter and Promoter Group0%0
Plea Charitable TrustShareholding of Promoter and Promoter Group0%0
Venus Foundation TrustShareholding of Promoter and Promoter Group0%0
Peeyush JainShareholding of Promoter and Promoter Group0%50
Akshansh ChaudharyShareholding of Promoter and Promoter Group0%1
Ashutosh JainShareholding of Promoter and Promoter Group0%0
Saransh ChaudharyShareholding of Promoter and Promoter Group0%0
Aditi K ChaudharyShareholding of Promoter and Promoter Group0%0
Ekta ThakurShareholding of Promoter and Promoter Group0%0
Monica JainShareholding of Promoter and Promoter Group0%0
Alka JainShareholding of Promoter and Promoter Group0%0
Board of Directors
NameDesignationYear
Pawan ChaudharyChairman / WTD / Managing Director / CFO2025
Manu ChaudharyWhole Time Director & JMD2025
Peeyush JainWhole Time Director / Deputy Managing Director2025
Ashutosh JainE D & Wholetime Director2025
Akshansh ChaudharyWhole Time Director & CTO2025
Navdeep SudIndependent Director2025
Savita GuptaIndependent Director2025
Pravindra Singh ChauhanIndependent Non Exe. Director2025
Nps MongaIndependent Non Exe. Director2025
Anil KumarIndependent Non Exe. Director2025
Jagdish Chander SharmaIndependent Non Exe. Director2025
Neha AroraCompany Sec. & Compli. Officer2025
Segments — Product
SegmentRevenueShare
Pharmaceutical Formulation₹0 Cr
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10201313
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-07Dividend (10/- per share)Final
dividend2026-08-07₹10 (100%)Final
forthcoming2026-07-20Board Meetings
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025300051551
20250000-22-22
2025000044
Insider / Designated-Person Trades

3 recent disclosure(s)

PAWAN CHAUDHARYAcquisition · 1,26,946
PAWAN CHAUDHARY RevisedAcquisition · 6,00,000
MANU CHAUDHARY RevisedAcquisition · 4,25,000
Company Information
Incorporated1989
ChairmanPawan Chaudhary
AuditorJ K Jain & Associates
Investor Email[email protected]; complianceoff
🌐 www.venusremedies.com

📍 S C No 857 Cabin No 10 2nd Flr, N A C Manimajra, Chandigarh, Chandigarh, 160101

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search